Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12038356 | 0.92 | LMNA (0.33) | LMNAMEN1KMT2AMAPTKDM4E | |
| SCHEMBL12038352 | 0.87 | LMNA (0.33) | LMNAMEN1KMT2AMAPTKDM4E | |
| SCHEMBL12038326 | 0.80 | MEN1 (0.33) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL12038362 | 0.79 | MAOB (0.34) | MEN1KMT2AMAPT | |
| SCHEMBL12038337 | 0.76 | KDM4E (0.36) | LMNAMEN1KMT2AMAPTKDM4E | |
| SCHEMBL12038354 | 0.76 | MAPT (0.33) | MAPT | |
| SCHEMBL12038347 | 0.74 | GLA (0.38) | LMNAMEN1KMT2AMAPTKDM4E | |
| SCHEMBL12038365 | 0.74 | MEN1 (0.31) | MEN1KMT2AMAPT | |
| SCHEMBL12038299 | 0.74 | MEN1 (0.39) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL12038292 | 0.73 | MAOB (0.37) | LMNAMEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318953-B2 | Reactive coumarin derivatives and their use in cellular analyses | AAT BIOQUEST, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318953-B2 | Reactive coumarin derivatives and their use in cellular analyses | AAT BIOQUEST, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110318772-A1 | REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES | AAT BIOQUEST, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110318772-A1 | REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES | AAT BIOQUEST, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318772-A1 | REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES | CYP3A7, XPO7, HCCS | LMNA 332/4885MEN1 3357/4885KMT2A 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.